Boston Scientific sued over patent settlement; Indiana nears top of powerful med tech states;

@FierceMedDev: Covidien plots job cuts, plant closures to save $300M. ICYMI yesterday | Follow @FierceMedDev

@DamianFierce: Ocular Therapeutix inches toward FDA approval with a panel thumbs-up. Story | Follow @DamianFierce

@MarkHFierce: A jury awarded Retractable Technologies $100M-plus in a patent lawsuit verdict against Becton Dickinson. Release | Follow @MarkHFierce

@MichaelGFierce: The artificial pancreas combines an with a continuous glucose monitor. Who will get one to market first? Special report from FierceDrugDelivery | Follow @MichaelGFierce

> A patent licensing firm with connections to Boston Scientific ($BSX) is suing the company for allegedly settling a number of lawsuits with St. Jude Medical ($STJ) without consulting it first. Item

> Chinese researchers say they've come up with a blood test that allows for much earlier detection of lung cancer. Story

> Indiana is now among the four biggest med tech U.S. states. Story

> SurModics ($SRDX), a maker of in vitro diagnostics technology, is shopping around for a board member, with news that chairman Robert Buhrmaster is retiring in February, 2014. Item

> California's Apama Medical, which is developing electrophysiology medical devices, raised $3.2 million in a Series A-1 financing. Item

> Wisconsin's VibeTech registered a new device with the FDA designed to help treat bone and muscle loss. Item

Biotech News

@FierceBiotech: ICYMI yesterday - Google's biotech plan: Partner with legendary CEO, tackle aging, think outside the cancer box. Article | Follow @FierceBiotech

@JohnCFierce: Bind (Langer) raised $70.5M in its IPO. Priced in the range. Press release | Follow @JohnCFierce

@EmilyMFierce: A molecular decoy could treat the most common type of human dwarfism. More via Science | Follow @EmilyMFierce

> San Diego biotech insider accused of shooting RNAi expert and brother-in-law. Report

> EU body endorses 11 new drugs from Glaxo, Roche, J&J and others. More

> Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII. Article

Pharma News

@FiercePharma: Sanofi CEO: Thanks to Genzyme, investors take us seriously. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: Ranbaxy's hair in tablet issue will shave its Q3 earnings, analyst tells ET. Report | Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Purdue hands California list of risky OxyContin prescribers. Article | Follow @CarlyHFierce

> GSK gets double dose of good news for Breo Ellipta. Story

> Sanofi rids itself of Zimulti suit, but its legacy weighs on new-generation obesity pills. More